Plural Hetero Atoms In The Tricyclo Ring System Patents (Class 514/291)
  • Publication number: 20140371259
    Abstract: A method for treating a neoplasm in a subject, comprising co-administering to the subject a therapeutically effective amount of an anticancer agent and a substituted 6,7-methylenedioxy-4-amino-quinoline, or a pharmaceutically acceptable salt or ester thereof.
    Type: Application
    Filed: January 29, 2013
    Publication date: December 18, 2014
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Barry I. Gold, Xiangqun Xie, Ajay Srinivasan, LiRong Wang
  • Publication number: 20140370071
    Abstract: Disclosed are drug delivery systems comprising drugs admixed with polymers having drug solubility gradients and methods of making the polymers. Also disclosed are medical devices having coatings thereon comprising the drug solubility gradient-containing polymers and at least one drug.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 18, 2014
    Inventors: Mingfei Chen, Peiwen Chen, Kishore Udipi
  • Publication number: 20140371207
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
    Type: Application
    Filed: December 13, 2013
    Publication date: December 18, 2014
    Applicants: Kyowa Hakko Kirin Co., Ltd., Millennium Pharmaceuticals, Inc.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Geraldine C.B. Harriman, Kenneth G. Carson, Shomir Ghosh, Amy M. Elder, Karen M. Mattia
  • Patent number: 8912215
    Abstract: In one aspect, the present invention is directed to a dry, flowable and compressible rapamycin composition comprising a specific mixture of hydrophobic and hydrophilic poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) block copolymers. In other aspects, the present invention is directed to a method of making the composition.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: December 16, 2014
    Assignee: Everon Biosciences, Inc.
    Inventors: Grzegorz Pietrzynski, Valery Alakhov, Kishore Patel
  • Patent number: 8911777
    Abstract: An oral tacrolimus composition comprises minicapsules having a core containing tacrolimus in a solubilized liquid form. The minicapsules have a release profile to release the pre-solubilized tacrolimus throughout the entire gastrointestinal tract. The composition may be used, for example, for treatment or prevention of solid organ transplant rejection.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: December 16, 2014
    Assignee: Sigmoid Pharma Limited
    Inventor: Ivan Coulter
  • Publication number: 20140363514
    Abstract: A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, core-shell particle formulation configured to independently release therapeutic agents from the core and the shell. Moreover, the core-shell particle bearing therapeutic agents enables treatment against the diseases such as cancer, inflammatory and auto-immune diseases.
    Type: Application
    Filed: August 21, 2014
    Publication date: December 11, 2014
    Applicant: AMRITA VISHWA VIDYAPEETHAM
    Inventors: MANZOOR KOYAKUTTY, PARWATHY CHANDRAN, ARCHANA P.R., SHANTIKUMAR NAIR
  • Publication number: 20140357651
    Abstract: The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.
    Type: Application
    Filed: May 4, 2012
    Publication date: December 4, 2014
    Inventors: Yi Liu, Pingda Ren, Katayoun Jessen, Xin Guo, Christian Rommel
  • Publication number: 20140357600
    Abstract: Described herein are compositions (e.g., a pharmaceutical composition) and methods for controlling the delivery of a therapeutic agent, and their use in the treatment and/or prevention of diseases and disorders.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 4, 2014
    Applicant: CHEMIC LABORATORIES INC.
    Inventors: Joseph P. St. Laurent, Scott A. Goodrich, Gerald S. Jones, Jr.
  • Publication number: 20140357660
    Abstract: Gene signatures for determining whether a neoplasm (such as a multiple myeloma neoplasm) is sensitive to mTORi/HDACi combination therapy and/or for determining the prognosis of a neoplasm in a subject are described. Some embodiments include determining whether a neoplasm is sensitive to mTORi/HDACi combination therapy by predicting whether mTORi/HDACi combination therapy will successfully treat the neoplasm, for example increasing survival of the subject with the neoplasm. In some embodiments, determining the prognosis includes predicting the outcome (such as chance of survival) of the subject with a neoplasm. Also disclosed are reagents, for example arrays, for use with the disclosed methods, as well as computer implementation of the disclosed methods.
    Type: Application
    Filed: November 12, 2012
    Publication date: December 4, 2014
    Inventors: Beverly A. Mock, John K. Simmons, Aleksandra Michalowski, Jyoti Patel
  • Publication number: 20140356407
    Abstract: A biodegradable in vivo supporting device is disclosed. The in vivo supporting device comprises a biodegradable metal scaffold and a biodegradable polymer coating covering at least a portion of the biodegradable metal scaffold, wherein the biodegradable polymer coating has a degradation rate that is faster than the degradation rate of the biodegradable metal scaffold.
    Type: Application
    Filed: July 31, 2014
    Publication date: December 4, 2014
    Inventor: Eric K. Mangiardi
  • Publication number: 20140358122
    Abstract: A drug coating layer which is a drug coating layer having a morphological form including a plurality of elongated bodies having long axes that each crystal of a water-insoluble drug independently has on a substrate surface, in which the long axes of the elongated bodies are nearly linear in shape, and the long axes of the elongated bodies form an angle in a predetermined range with respect to a substrate plane with which the long axis of the elongated body intersects. The drug coating layer can provide low toxicity and a high intravascular stenosis inhibitory effect.
    Type: Application
    Filed: June 19, 2014
    Publication date: December 4, 2014
    Applicant: Terumo Kabushiki Kaisha
    Inventors: Keiko YAMASHITA, Hiroshi Goto, Shigenori Nozawa, Katsumi Morimoto, Hiroaki Kasukawa
  • Publication number: 20140348926
    Abstract: The application discloses a formulation and method for increasing bioavailability of an orally administered drug.
    Type: Application
    Filed: January 17, 2013
    Publication date: November 27, 2014
    Inventors: Amnon Hoffman, Abraham J. Domb, Anna Elgart, Irina Cherniakov
  • Publication number: 20140349968
    Abstract: The instant invention provides a method of treating a cancer selected from the group consisting of non-small cell lung cancer and breast cancer with an mTOR inhibitor and an ?v62 3 integrin antagonist, wherein the mTOR inhibitor is ridaforolimus, everolimus, temsirolimus or a combination thereof.
    Type: Application
    Filed: April 30, 2014
    Publication date: November 27, 2014
    Applicants: ARIAD Pharmaceuticals, Inc., Merck
    Inventors: Jennifer O'Neil, Yair Benita, Shane Marine, Brian Haines
  • Publication number: 20140348758
    Abstract: This invention relates to a solution formulation containing a tiotropium salt, 12-20% ethanol, 0.1-1.5% of water, 0.05-0.10% citric acid (or other organic acid) and an HFA propellant, wherein the percentages are percentages by weight based on the total weight of the formulation. The invention also provides a pMDI comprising a canister containing the formulation.
    Type: Application
    Filed: December 6, 2012
    Publication date: November 27, 2014
    Inventor: Xian-Ming Zeng
  • Publication number: 20140343091
    Abstract: Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Applicant: NOVARTIS AG
    Inventors: Bernard Cuenoud, Ian Bruce, Robin Alec Fairhurst, David Beattie
  • Publication number: 20140343090
    Abstract: A method and device for local delivery of a water-insoluble therapeutic agent to the tissue of a normal or diseased body lumen is disclosed. An expandable structure of a medical disposable device, such as a balloon of a balloon catheter, is coated with a non-durable coating which comprises poly(HEMA) complexed with iodine and has a substantially water-insoluble therapeutic agent dispersed therein. The medical disposable device is inserted into a body lumen, and expanded to contact the non-durable coating against the body lumen and deliver the substantially water-insoluble therapeutic agent to the body lumen tissue.
    Type: Application
    Filed: April 16, 2014
    Publication date: November 20, 2014
    Applicant: COVIDIEN LP
    Inventors: Eugene T. Michal, Matthew J. Pollman
  • Patent number: 8889704
    Abstract: Compounds of Formula I: in which R1, R2, R3, R4 and R10 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: November 18, 2014
    Assignee: Array BioPharma Inc.
    Inventors: James F. Blake, Robert Kirk Delisle, Lisa A. De Meese, James M. Graham, Yvan Le Huerou, Michael Lyon, John E. Robinson, Eli M. Wallace, Bin Wang, Rui Xu
  • Patent number: 8889705
    Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. While the antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer activity, and has a safe pharmacological profile in humans, structure-function analyzes pointed to a proton at position 9 of the isoquinoline ring that can be modified without compromising tubulin binding activity. Noscapine analogs with various functional moieties at position 9 on the isoquinoline ring kill human cancer cells resistant to other anti-microtubule agents, such as vincas and taxanes.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: November 18, 2014
    Assignee: Emory University
    Inventors: Harish C. Joshi, Ritu Aneja, Surya N. Vangapandu
  • Publication number: 20140335194
    Abstract: Disclosed are a polymeric drug carrier-containing pharmaceutical composition with enhanced stability in its solution state and a method for stabilizing the same. More particularly, disclosed are a pharmaceutical aqueous solution composition for storage under refrigeration containing a polymeric drug carrier comprising an amphiphilic block copolymer comprised of a hydrophilic block and a hydrophobic block, and a polylactic acid derivative fixed with a di- or tri-valent metal ion at its terminal carboxyl group and having preservation stability for at least 6 months, preferably at least 12 months when stored under refrigeration, and a method for stabilizing the same.
    Type: Application
    Filed: December 7, 2012
    Publication date: November 13, 2014
    Inventors: Sa-Won Lee, Joong-Woong Cho, Gyeong-Hae Kim, Min-Hyo Seo
  • Publication number: 20140336154
    Abstract: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: July 29, 2014
    Publication date: November 13, 2014
    Inventors: Steven Do, Richard Goldsmith, Tim Heffron, Aleksandr Kolesnikov, Steven Staben, Alan G. Olivero, Michael Siu, Daniel P. Sutherlin, Bing-Yan Zhu, Paul Goldsmith, Tracy Bayliss, Adrian Folkes, Neil Pegg
  • Publication number: 20140336215
    Abstract: A method of treating rhinitis and rhinorrhea includes taking a daytime oral dosage unit containing a non-sedating antihistamine for treating rhinitis and an anticholinergic agent having limited capacity to cross blood-brain barrier for treating rhinorrhea, and taking a nighttime oral dosage unit containing a non-sedating anticholinergic agent that has limited capacity to cross blood-brain barrier and that is in a lower amount than the amount in the daytime oral dosage unit for treating rhinorrhea or no anticholinergic agent.
    Type: Application
    Filed: July 22, 2014
    Publication date: November 13, 2014
    Inventors: Robert E. Weinstein, Allan M. Weinstein
  • Patent number: 8883214
    Abstract: The present invention provides compositions and methods for treating ocular disorders such as myopia.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: November 11, 2014
    Assignee: The Regents of the University of California
    Inventors: Christine F. Wildsoet, James Su, Kevin E. Healy
  • Publication number: 20140329848
    Abstract: Provided herein is technology relating to deuterated amlexanox and particularly, but not exclusively, to compositions comprising deuterated amlexanox, methods of producing deuterated amlexanox, and uses of deuterated amlexanox.
    Type: Application
    Filed: May 2, 2014
    Publication date: November 6, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Alan R. Saltiel, Hollis D. Showalter, Scott Larsen
  • Publication number: 20140328778
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Patent number: 8877771
    Abstract: The present invention is directed to the use of rapamycin derivatives for use in treating solid tumors, optionally in combination with a chemotherapeutic agent.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: November 4, 2014
    Assignee: Novartis Pharmaceuticals Corporation
    Inventors: Heidi Lane, Terence O'Reilly, Jeanette Marjorie Wood
  • Patent number: 8877251
    Abstract: The present invention relates to methods of making a powder for inhalation comprising a first step of mixing particles of a force-controlling agent selected from the group consisting of phospholipids, titanium dioxide, aluminum dioxide, silicon dioxide, starch, and salts of fatty acids, with particles of one or more pharmacologically active materials, wherein the mixing is achieved by one or more of the processes of sieving, mixing or blending, and wherein the mixing results in the particles of the force-controlling agent being disposed on the surface of the particles of the one or more pharmacologically active materials as either a particulate coating or as a continuous or discontinuous film.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: November 4, 2014
    Assignee: Jagotec AG
    Inventor: Rudi Mueller-Walz
  • Publication number: 20140322291
    Abstract: The present invention is related to a medical device carrying at least on a portion of its surface at least one drug or drug preparation and at least one lipophilic lubricant at a ratio of 0.1-500% by weight of the at least one lubricant in relation to 100% by weight of the drug, wherein the at least one drug is selected of paclitaxel, arsenic trioxide, and lipophilic derivatives of corticoids and selected Limus drugs, and the at least one lipophilic lubricant is a C6-C30-monocarboxylic acid salt.
    Type: Application
    Filed: December 14, 2012
    Publication date: October 30, 2014
    Applicant: INNORA GMBH
    Inventors: Madeleine Caroline Berg, Thomas Speck
  • Publication number: 20140322242
    Abstract: Methods of treating or preventing cancer, or ameliorating a symptom thereof, by administering a muscarinic receptor inhibitor to inhibit cancer metastasis and/or a ? adrenergic receptor inhibitor to inhibit tumor initiation are provided. Also provided are pharmaceutical compositions for treating or preventing cancer comprising a muscarinic receptor inhibitor and/or a ? adrenergic receptor inhibitor.
    Type: Application
    Filed: November 24, 2011
    Publication date: October 30, 2014
    Applicant: Icahn School of Medicine at Mount Sinai
    Inventors: Paul S. Frenette, Claire Magnon
  • Publication number: 20140323515
    Abstract: This invention relates to novel crystalline forms of tiotropium bromide, processes for preparing them, and their use in pharmaceutical formulations.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 30, 2014
    Inventors: Nicola DIULGHEROFF, Francesca SCARPITTA, Alessandro PONTIROLI, Adrienne KOVACSNE-MEZEI, Judith ARONHIME, Alexandr JEGOROV
  • Patent number: 8871238
    Abstract: Biodegradable polymers useful for fabricating implantable medical devices and as coatings for medical devices are provided. The biodegradable polymers are biocompatible and can be tuned to provide optimum bioactive agent elution rates as well as degradation rates. Also provided are methods for making medical devices and medical device coatings using the biodegradable polymers.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: October 28, 2014
    Assignee: Medtronic Vascular, Inc.
    Inventors: Peiwen Cheng, Mingfei Chen, Kishore Udipi
  • Publication number: 20140315927
    Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: Andrew Simon Bell, lain Brian GARDNER, Karl Richard GIBSON, David Cameron PRYDE, Florian Michel WAKENHUT
  • Publication number: 20140314882
    Abstract: Combinations of compounds are provided that produce a synergistic effect when administered.
    Type: Application
    Filed: June 27, 2014
    Publication date: October 23, 2014
    Inventors: Frederick P. ROTH, Murat COKOL, Hon Nian CHUA
  • Publication number: 20140315942
    Abstract: The present invention is drawn to formulations for the transdermal delivery of rapamycin or other related compounds. Specifically, in one embodiment a formulation for transdermally delivering rapamycin includes an mTOR inhibitor, such as rapamycin, water, a polymer having surfactant properties, a polymer having thickening properties, a solvent for solubilizing the mTOR inhibitor, a glycol, a C10-C20 fatty acid; and a base.
    Type: Application
    Filed: January 24, 2014
    Publication date: October 23, 2014
    Applicant: TRANSDERM, INC.
    Inventors: Roger L. Kaspar, Tycho Speaker
  • Patent number: 8865189
    Abstract: Implantable medical devices including a coating having a bioactive agent and a poly(ester amide) polymer. Methods of forming these coatings are also described.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: October 21, 2014
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Lothar Walter Kleiner, Jessica Reneé DesNoyer, Stephen Dirk Pacetti, Syed Faiyaz Ahmed Hossainy, O. Mikael Trollsas, Michael Huy Ngo
  • Publication number: 20140309253
    Abstract: The invention relates to compounds of the formula wherein R?, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 16, 2014
    Inventors: Bertrand Leblond, Cedric Chauvignac, Thierry Taverne, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Desire, Matthew P. Pando, John E. Donello, Rong Yang
  • Publication number: 20140308333
    Abstract: A coating material including a bio-absorbable cross-linked material and a cellular uptake inhibitor. The bio-absorbable cross-linked material includes two or more fatty acids cross-linked into a substantially random configuration by ester bonds. The coating material may be adhered to a medical device. A medical device system including a medical device and a coating is also included.
    Type: Application
    Filed: April 14, 2014
    Publication date: October 16, 2014
    Applicant: ATRIUM MEDICAL CORPORATION
    Inventors: Roger Labrecque, Geoffrey Moodie, Joseph F. Ferraro, Lisa Rogers, Paul Martakos, Theodore Karwoski, Steve A. Herweck
  • Publication number: 20140309181
    Abstract: Small compounds that modulate the expression of and/or function of sodium channel, voltage-gated, alpha subunit (SCNxA) are presented. Pharmaceutical compositions containing such small molecules and their use in treating diseases and disorders associated with the expression of SCNxA are also presented.
    Type: Application
    Filed: August 28, 2012
    Publication date: October 16, 2014
    Applicant: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Jane H. Hsiao
  • Publication number: 20140309185
    Abstract: This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.
    Type: Application
    Filed: October 26, 2012
    Publication date: October 16, 2014
    Inventors: Alexander Keith Stewart, Artem Plekhov, Robert Greenhouse
  • Patent number: 8859529
    Abstract: This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: October 14, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Bandarpalle B. Shankar, Seong Heon Kim, Wensheng Yu, Ling Tong, Michael K. C. Wong, Brian J. Lavey, Joseph A. Kozlowski, Lei Chen, Razia K. Rizvi, Aneta Maria Kosinski, De-Yi Yang, Guowei Zhou, Kristen E. Rosner, Luke Fire, Judson E. Richard, Dansu Li
  • Patent number: 8859585
    Abstract: Provided are methods and compositions for the treatment of depression and anxiety. The compositions contain scopolamine, or an analog thereof, and can optionally include one or more psychoactive agents. Further provided is an inhaler containing scopolamine, or an analog thereof, in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: October 14, 2014
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Maura L. Furey, Wayne C. Drevets
  • Publication number: 20140303201
    Abstract: The subject invention provides for cancer therapy.
    Type: Application
    Filed: April 7, 2014
    Publication date: October 9, 2014
    Inventor: Malka COHEN-ARMON
  • Publication number: 20140303091
    Abstract: Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof topical ophthalmic compositions containing norketotifen.
    Type: Application
    Filed: April 15, 2014
    Publication date: October 9, 2014
    Inventors: A.K. Gunnar Aberg, Keith Johnson
  • Publication number: 20140303708
    Abstract: A medical assembly is disclosed comprises a stent and a catheter having a balloon, wherein the coefficient of friction and/or the adhesion at the stent/balloon interface are reduced.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Inventors: Stephen R. Dugan, Jessica R. DesNoyer, Stephen D. Pacetti, Bozena Zofia Maslanka
  • Publication number: 20140294912
    Abstract: Implantable devices formed of or coated with a material that includes an amorphous poly(D,L-lactide) formed of a starting material such as meso-D,L-lactide are provided. The implantable device can be used for the treatment, mitigation, prevention, or inhibition of a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventors: Stephen D. Pacetti, Syed Faiyaz Ahmed Hossainy, David C. Gale
  • Publication number: 20140294726
    Abstract: Methods for diagnosing and treating Alzheimer's disease are provided. In particular, methods of restoring blood-brain barrier integrity and/or promoting vascular reversion in a person suffering from Alzheimer's disease by administering an anti-angiogenic agent or an agent that is capable of restoring tight junction integrity. Methods of preventing or delaying the onset of Alzheimer's disease in a subject are also provided.
    Type: Application
    Filed: July 18, 2012
    Publication date: October 2, 2014
    Inventors: Wilfred Jefferies, Kaan E. Biron, Dara L. Dickstein
  • Publication number: 20140296228
    Abstract: Compounds of formula I: wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.
    Type: Application
    Filed: February 28, 2014
    Publication date: October 2, 2014
    Applicant: Gilead Sciences, Inc.
    Inventors: Youla S. Tsantrizos, Murray D. Bailey, Francois Bilodeau, Rene Coulombe, Teddy Halmos, Stephen Kawai, Serge R. Landry, Steven LaPlante, Sebastien Morin, Marc-Andre Poupart, Bruno Simoneau, Lee Fader, Rebekah J. Carson, Mathieu Parisien
  • Publication number: 20140296272
    Abstract: The present invention relates to a series of compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutic amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventors: Dorothée Bardiot, Patrick Chaltin, Frauke Christ, Zeger Debyser, Marc De Maeyer, Arnaud Marchand, Damien Marchand, Arnout Voet
  • Publication number: 20140296279
    Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.
    Type: Application
    Filed: April 27, 2012
    Publication date: October 2, 2014
    Applicants: Mercator MedSystems, Inc., Abraxis BioScience, LLC
    Inventors: Kirk Seward, Neil P. Desai
  • Patent number: 8846926
    Abstract: This invention relates to novel crystalline forms of tiotropium bromide, processes for preparing them, and their use in pharmaceutical formulations.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: September 30, 2014
    Assignee: Sicor Inc.
    Inventors: Nicola Diulgheroff, Francesca Scarpitta, Alessandro Pontiroli, Adrienne Kovacsne-Mezei, Judith Aronhime, Alexandr Jegorov
  • Publication number: 20140288097
    Abstract: The present invention provides methods of identifying an agent or drug candidate molecule, validating a target, and identifying normalizing therapeutics that modulates translation, such as in an oncogenic signaling pathway, in a biological sample as determined by translational profiling of one or more genes in the biological sample. The present invention also provides diagnostic and therapeutic methods using the translational profiling methods described herein.
    Type: Application
    Filed: February 7, 2014
    Publication date: September 25, 2014
    Applicant: The Regents of The University of California
    Inventors: Davide Ruggero, Andrew Hsieh, Merritt Edlind, Kevan M. Shokat, James Appleman, Steve Worland